Sartorius opens German production facility for bioreactors

Friday, September 14, 2012 12:19 PM

Sartorius, the Germany-based international laboratory and process technology provider, has officially opened its new plant in Guxhagen, Germany, for the manufacture of bioreactors.

After approximately one year of construction and $23.5 million, the new building will now manufacture bioreactors and further production equipment for customers in the biopharmaceutical industry. Covering a total area of nearly 10,000 square feet, the new building complex provides space for a high-tech manufacturing hall and offices for 240 employees. The building owner is Robos GmbH, from which Sartorius has rented the premises in a long-term lease.

"The new plant enables us to substantially enhance our manufacturing processes and creates additional capacity for us in view of the rising demand for biopharmaceutical production equipment,” said Joachim Kreuzburg, CEO and executive board chairman, Sartorius. “As a result, we are optimally prepared for further expansion, especially for single-use bioreactors.”

Sartorius has moved all operations from its former bioreactor production facility in Melsungen, Germany, where it had reached maximum capacity limits.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 29

WCG sees ePharmaSolutions’ clinical trial portal as the next step in the data evolution, company mission

Cutting-edge advertising can ‘break through the clutter’ for successful patient recruitment

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

September

Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs